Akèy › Kansè kolorektal › Colorado › Denver
Etid klinik pou Kansè kolorektal nan Denver, CO
23 etid pou Kansè kolorektal ap chèche patisipan nan sit nan ak bò kote Denver (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Kaiser Permanente-Franklin, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Rocky Mountain Cancer Center, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- AdventHealth Porter, Denver
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Intermountain Health Cancer Center Saint Joseph, Denver
- Intermountain Health Saint Joseph Hospital - Research Office, Denver
- Intermountain Health Saint Joseph Hospital, Denver
- ak 3 plis
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute (SCRI), Denver
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Ap rekriteFaz 3
- Rocky Mountain Cancer Centers, Denver
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Ap rekriteFaz 3
- Rocky Mountain Cancer Centers, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Ap rekriteFaz 1/2
- SCRI at HCA Health One, Denver
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Ap rekriteFaz 1
- SCRI Denver, Denver
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthOne, Denver
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Ap rekriteFaz 1
- Sarah Cannon Research Institue At Healthone, Denver
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Rocky Mountain Cancer Centers, LLP, Denver
- Rocky Mountain Cancer Centers, LLP, Denver
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthONE, Denver
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Ap rekriteFaz 1
- Context Investigational Site, Denver
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Ap rekriteFaz 2
- Rocky Mountain Cancer Center - Primary, Denver
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthONE, Denver
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Ap rekriteFaz 1/2
- SCRI - Denver, Denver
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1
- Sarah Cannon Cancer Institute at HealthONE, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- ak 1 plis
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
Etid Kansè kolorektal nan lòt vil
- Houston, TX102 etid
- New York City, NY78 etid
- Nashville, TN69 etid
- Boston, MA63 etid
- Los Angeles, CA59 etid
- Arlington, VA52 etid
- St. Louis, MO50 etid
- San Antonio, TX46 etid
- Philadelphia, PA44 etid
- Grand Rapids, MI40 etid
- Baldwin Park, CA37 etid
- Chicago, IL34 etid
Lòt etid nan Denver
- Kansè Metastatik29 etid
- Kansè nan tete29 etid
- Kansè Poumon ki pa ti selil27 etid
- Myelom Miltip27 etid
- Melanom19 etid
- Kansè pwostat19 etid
- Kansè (tout kalite)18 etid
- Kansè ovè16 etid
- Kansè poumon16 etid
- Kansè Endomèt15 etid
- Limfòm Non-Hodgkin14 etid
- Kansè pankreyas13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.